1. Scrip
  2. >>Therapy Areas

APPROVED: Genentech/Roche Gazyva 1st breakthrough-designated drug to enter US market

 
• By Donna Young

Roche US unit Genentech made history on 1 November as the first company to have an FDA-designated breakthrough therapy gain th agency’s blessing to enter the US market – Gazyva (obinutuzumab/GA101), which won approval in combination with chlorambucil as a therapy for treatment-naïve chronic lymphocytic leukemia (CLL).

Roche US unit Genentech made history on 1 November as the first company to have an FDA-designated breakthrough therapy gain th agency’s blessing to enter the US market – Gazyva (obinutuzumab/GA101), which won approval in combination with chlorambucil as a therapy for treatment-naïve chronic lymphocytic leukemia (CLL).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.